Meglithan (Metformin Hydrochloride, Linagliptin)

Metformin hydrochloride lowers blood sugar primarily by inhibiting hepatic gluconeogenesis, which reduces the amount of glucose released by the liver. It also enhances peripheral insulin sensitivity, allowing muscle and fat tissues to take up glucose more effectively, thereby contributing to overall glycemic control.

Linagliptin is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor. By blocking DPP‑4, it prolongs the activity of incretin hormones such as GLP‑1 and GIP, which stimulate insulin release and suppress glucagon secretion in a glucose‑dependent manner, helping to lower post‑prandial and fasting glucose levels.

The appropriate dose of Meglithan is determined by the prescribing healthcare professional based on the patient’s individual clinical condition, renal function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

To order Meglithan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin monotherapy, Meglithan adds a DPP‑4 inhibitor, offering greater HbA1c reduction and improved post‑prandial glucose control. Unlike sulfonylureas, it has a lower risk of hypoglycemia and does not cause weight gain. It provides a convenient fixed‑dose option versus taking two separate tablets.

Meglithan tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Meglithan is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or split unless specifically advised by a healthcare professional.

The most serious risks include lactic acidosis from metformin, which is rare but potentially fatal, and severe hypoglycemia when combined with insulin or sulfonylureas. Pancreatitis and allergic reactions such as rash or anaphylaxis are also rare but require immediate medical attention.

Meglithan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, linagliptin, or any component of the formulation, and in those with acute or unstable heart failure. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.